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RECEIVED DATE  
Abstract: Resistance to combretastatin A-4 is mediated by metabolic modification of the phenolic 
hydroxyl and ether groups of the 3-hydroxy-4-methoxyphenyl (B ring). Replacement of the B ring of 
combretastatin A-4 by a N-methyl-5-indolyl reduces tubulin polymerization inhibition (TPI) and 
cytotoxicity against human cancer cell lines but cyano, methoxycarbonyl, formyl, and 
hydroxyiminomethyl substitutions at the indole 3-position restores potent TPI and cytotoxicity against 
sensitive human cancer cell lines. These highly potent substituted derivatives displayed low nanomolar 
cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle 
analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies and promoted cell 
killing mediated by caspase-3 activation. Binding at the colchicine site was suggested by molecular 
modeling studies. Substituted combretastatins displayed higher potencies than the isomeric 
isocombretastatins and the highest potencies were achieved for the hydroxyiminomethyl (21) and cyano 
(23) groups, with TPI values in the submicromolar range and cytotoxicities in the subnanomolar range. 
Dose-response and time-course studies showed that drug concentrations as low as 1 nM (23) or 10 nM 
(21) led to a complete G2/M cell cycle arrest after 15 h treatment followed by a high apoptosis-like cell 
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response after 48-72 h treatment. The P-glycoprotein and calcium antagonist verapamil increased 21 and 
23 cytotoxicity to IC50 values of 10-10 M, and highly potentiated the cytotoxic activity in 100-fold of the 
CHO derivative (17), in A549 human non-small cell lung cancer cells. The differences in cytotoxic 
potency observed between the highly potent cyano (23) and hydroxyiminomethyl (21) groups and other 
substituents with similar TPI values (17) were very much reduced upon co-treatment with verapamil. A 




Microtubules and their main constituents the αβ-tubulin heterodimers are the targets of many anti-tumor 
and anti-parasitic drugs that disrupt their dynamical equilibrium. Microtubule-targeting agents (MTAs) 
can affect cell shape maintenance, trafficking, cilia and flagella functioning, signaling, and mitosis as 
some of the many functions of microtubules in the cells. Several drug binding sites different from the 
nucleotide binding sites have been described, with at least seven structurally characterized, including the 
taxanes, the vinca alkaloids, the colchicine, the laulimalide/peloruside, the maytansine, the pironetin, 
and the hemiasterlin sites located in both the α and β tubulins. Some MTA stabilize the microtubules, as 
for example paclitaxel, while other destabilize them, as for instance colchicine, but at low 
concentrations all of them affect the polymerization/depolymerization dynamics.1 
The pivotal role of microtubules in mitosis, together with their role as scaffolds for signaling molecules 
modulating apoptosis, makes them a major target in cancer chemotherapy, and thus MTAs lead to cell 
cycle arrest at G2/M phase and late apoptosis.2 Inhibition of the mitotic spindle is the most common 
signature of MTAs in cell treatment, and therefore they are often referred to as anti-mitotic agents, 
although other mechanisms are probably important in their in vivo anti-tumor effects.3, 4 In fact, 
colchicine site binding drugs as for instance the combretastatins (Figure 1) are often considered vascular 
disrupting agents (VDA), because in vivo they cause a rapid collapse of the tumor associated 
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vasculature and blood flow shutdown which is mainly responsible for tumor death.5, 6 The emergence of 
VDAs holds great potential in the treatment of malignant solid tumors, and the 3-O-phosphate prodrug 
of combretastatin A-4 (CA4P), the more effective CA1P (Oxi4503) and the amino analogue AVE8062 
are undergoing preclinical and clinical development.7 However, despite a rapid initial central tumor 
necrosis after VDAs treatment, a peripheral rim of resistant viable cancer cells remains and eventually 
grow to the necrotic area causing recurrence and metastasis.8, 9 Several strategies have been applied to 
increase the clinical efficiency of combretastatins, including combinations with antiangiogenic drugs or 
with other antitumor agents or the development of more potent derivatives. 
 



















Innate or acquired resistance mechanisms employed by cancer cells against treatment with 
combretastatin A-4 have been described, including adaptation to the hypoxic conditions and 
reestablishment of the vasculature in response to the reduction in blood supply as well as direct 
resistance to the drug. The B ring of combretastatin A4 through its hydroxyl group provides the 
attachment point for prodrug formation thus allowing pharmacokinetic optimization but it is also its 
Achilles´ heel struck by phase I and II metabolic reactions associated with its inactivation, as shown for 
resistant hepatocellular carcinoma or colon adenocarcinoma-derived HT-29 cells.10-12 
We have previously shown that an indole ring is a suitable replacement for the B ring of combretastatin 
A4 in the context of a 1,1-diarylethene (isocombretastatin) skeleton (Fig. 1).13 Substitutions of the indole 
3 position did not result in improvements with respect to the parent unsubstituted indole. Surprisingly, 
the isomeric indole combretastatin (1,2-diarylethene) showed much lower potency.14 Here we show that 
introduction of substituents at the 3 position of indole combretastatin improves on the tubulin inhibitory 
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activity. Furthermore, the cytotoxicity of compounds with similar tubulin inhibitory potency against 
combretastatin A4 resistant colon adenocarcinoma (HT-29) and lung adenocarcinoma (A-549) cell lines 
is dependent on minor structural changes and can be further improved upon combination with 
verapamil. Our results suggest that MDR efflux is an important factor in the observed cytotoxicity 
differences and that substitution at the indole 3 position with appropriate substituents such as the cyano 
or hydroxyimino groups greatly reduces the compounds’ efflux and result in apoptotic-like cell death 
after complete G2/M cell cycle arrest after very low dose (1nM) drug treatments. 
 
RESULTS AND DISCUSSION 
Chemical synthesis 
The synthesis of combretastatins was carried out by the usual Wittig procedure, followed by 
derivatization at 3-position of the indoles. The indole aldehydes used as starting materials 1-5, were 
obtained from commercial 1H-indole-5-carboxaldehyde (Scheme 1), whereas 1H-benzo[d]imidazole-5-
carboxylic acid (6) was used to prepare the corresponding 1-methyl-1H-benzo[d]imidazole-5(6)-
carbaldehydes (9 and 10, Scheme 2). Indole-combretastatins unsubstituted at 3-position 13, 1514 and 16 
were respectively synthesized by Wittig olefination of 1 and 2 with 3,4,5-trimethoxybenzyl bromide 
(11) and 2 with 2,3,4-trimethoxybenzyl bromide (12) (Scheme 1). 15 and 16 were readily formylated at 
3-position,15 to yield 17 and 18 (Scheme 3), the two latter used to prepare derivatives at this position 19-
34. 
To complete the series of compounds to assay, the aldehyde 14, bromoderivatives 35 and 36 (Scheme 
1), and the benzimidazole-combretastatins (Scheme 2) seemed adequate to fulfil the structural 
modifications of indole related derivatives. The unresolved mixture of 1-methyl-1H-benzimidazole-
5(6)-carbaldehydes (9+10), obtained by methylation of 1H-benzimidazole-5(6)-carbaldehyde (8), was 




Once separated from the E-aldehydes, several transformations aimed at increasing solubility by means 
of additional nitrogen or oxygen atoms were made, Z-aldehydes 17 and 18 were reduced to the alcohols 
19 and 20, transformed into the oximes16, 17 21 (Z+E) and 22 (Z+E) and oxidized to carboxylic acids18 
25 and 26. In addition, the oximes by treatment with acetic anhydride in pyridine, were converted into 
the nitriles 23 and 24 and the carboxylic acid 25 was transformed into its methyl ester 27.  
 
Scheme 1: Synthesis of 3-indolecarbaldehyde combretastatin derivatives 13-16 and 
bromoderivatives 35 and 36.a 
 
(a) (i) (3,4,5-(MeO)3PhCH2)Ph3PBr (11), THF, BuLi (1.6M), THF, -40ºC, 1h; (ii) 1-ethyl-1H-indole-5-
carbaldehyde (1), 1-methyl-1H-indole-5-carbaldehyde (2), 1-ethyl-1H-indole-3,5-dicarbaldehyde (3), 1-
methyl-3-bromo-1H-indole-5-carbaldehyde (4) or 1-methyl-2,3-dibromo -1H-indole -5-carbaldehyde 
(5), THF, -40 ºC to rt, 24 h. (b) (i) (2,3,4-(MeO)3PhCH2)Ph3PBr (12), THF, BuLi (1.6M), THF, -40ºC, 
1h; (ii) 1-methyl-1H-indole-5-carbaldehyde (2), THF, -40 ºC to rt, 24 h. 
 




Reagents and conditions: (a) (i) Ph3P(3,4,5-MeO3PhCH2)I, THF, nBuLi (1.6M), THF, -40 ºC, 1h; (ii) 1-
methyl-1H-benzimidazole-5(6)-carbaldehydes, THF, -40 ºC to rt, 24 h. 
 
Scheme 3: Preparation of 3-substituted indole-combretastatin derivatives 17-34.a 
 
Reagents and conditions: (a) (i) POCl3, DMF, 0 ºC, 1 h; (ii) 15 or 16, 60 ºC, 2 h. (b) NaBH4, MeOH, rt, 
30 min. (c) NH2OH·HCl, MeOH, pyr (2 drops), rt, 24 h. (d) Ac2O, pyr, rt, 4 h. (e) 17 or 18 in tBuOH, 2-
methyl-2-butene, THF; add NaClO2, NaH2PO4, H2O, rt, 12 h. (f) TMSCHN2, MeOH, 15 min. (g) (i) 
NH2CH2COOEt·HCl; EDCI; 4-DMAP; rt, 48 h, inert atmosphere. (h) CH3NHCH2COOMe·HCl; EDCI; 
4-DMAP; rt, 48 h, inert atmosphere. (i) NH2CH2CH2COOEt; EDCI; 4-DMAP; rt, 48 h, inert 
atmosphere. (j) (COOMe)2CHNH2·HCl; EDCI; 4-DMAP; rt, 48 h, inert atmosphere. (k) KOH/MeOH, 




Other transformations include the formation of several amides from the carboxylic acid 25, using 
different aminoesters (Scheme 3).19 Thus, the amides 28, 29, 30 and 31 were obtained by treatment with 
glycine ethyl ester, sarcosine methyl ester, β-alanine ethyl ester and dimethyl aminomalonate. By 
saponification with KOH/MeOH the carboxylic acids 32, 33 and 34 were obtained. 
With these compounds, representative structures of the 3-substituted 1-methyl-1H-indole 
combretastatins were at hand in order to explore the effect of this substitution on their activities.  
 
Aqueous solubility 
Aqueous solubility in phosphate buffer at pH 7.0 was determined using a shake-flask method, 
microfiltration and UV absorbance measurement of soluble compound. N-methylindole combrestatatins 
with hydrogen at C-3 (13, 15 and 16) display aqueous solubility similar to Combretastatin A-4 (Table 
1). Cyano or bromine substituents do not improve aqueous solubility but a carboxylic acid or amides of 
aminoacids increase the solubility between 40 and 150 times.  
Table 1. Aqueous solubility of representative compounds in aqueous buffer pH 7.0 
Compound Solubility (µg/mL) Compound 
Solubility 
(µg/mL) 
CA-4 1.0420 25 80.0 
13 2.0 27 1.0 
15 2.6 29 60.0 
16 2.0 33 380.0 
17 6.0 34 352.0 
19 3.0 35 2.0 




The effect of the synthesized compounds on cell viability against four types of human cancer cell 
lines: A-549 human lung carcinoma, HeLa human cervix epithelioid carcinoma, HL-60 human acute 
myeloid leukemia, and HT-29 human colon adenocarcinoma was assayed by the XTT method.21 The 
results are summarized in Table 2. The compounds are cytotoxic at concentrations between micromolar 
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and subnanomolar, thus indicating that the combination of a trimethoxyphenyl and a 5-indolyl forming a 
Z stilbene skeleton is a very favorable scaffold for cytotoxicity. The most potent compounds of the 
series inhibited proliferation of the indicated human cancer cell lines at very low drug concentrations, 
with IC50 values in the 10−9 M and 10−10 M range. These IC50 values were up to 10−100 times lower 
than those shown by doxorubicin (IC50 at a range of 10−8 M). For most compounds the IC50 are similar 
for HL60 and HeLa whereas they are higher for A-549 and HT-29, a difference in sensitivity which has 
been previously observed for other colchicine site ligands.10, 13 
 
Table 2. Tubulin Polymerization Inhibitory Activity, Cytotoxic Activity against Human Cancer Cell 









 RN X Y Z R2 
%TPI 





















13 Et OMe H CH H 95 2.0 0.172 0.919 0.27 0.434 -10.31 
(1//93) 
14 Et OMe H C-CHO H 95 1.2 0.03 >10 0.029 3.10 -10.40 
(1//65) 
15 Me OMe H CH H  2.0  0.47  0.36 -9.80 
(1//96) 
16Z Me H OMe CH H 100a >5 0.0059 1.7 0.062 0.086 -9.24 
(2//41) 
16E Me H OMe CH H 59 4-5 0.0039 0.0046 0.0066 0.0058  
17 Me OMe H  C-CHO H 98 0.5 0.0065 4.7 0.00073 0.6 -10.34 
(1//85) 
18 Me H OMe C-CHO H 97 >5 0.0087 7.9 0.043 0.6 -9.74 
(2//23) 
19 Me OMe H  C-CH2OH H 91 1.2 0.028 0.045 0.032 0.033 -10.47 
(1//79) 
20 Me H OMe C-CH2OH H 45 ≈20 8.5 3.9 1.2 1.0 -9.62 
(2//20) 










22 Me H OMe C-CH=NOH H 50 ≈20 1.0 2.1 0.33 0.97  
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24 Me H OMe C-CN H 87 >5 0.21 0.7 0.13 0.41 -10.10 
(2//6) 
25 Me OMe H  C-COOH H 95 1.4 0.0072 0.087 0.033 0.065 -9.73 
(1//53) 
26 Me H OMe C-COOH H 7 >20 3.1 3.0 3.9 2.9 -9.17 
(2//24) 
27 Me OMe H  C-COOMe H 95 0.7 0.0062 0.041 0.0073 0.022 -10.16 
(1//19) 
29 Me OMe H  C-CON(Me) (CH2)2COOMe 
 95 >20 0.305 0.159 1.6 0.235  
30 Me OMe H  C-CONH (CH2)2COOEt 
 100 3.0      
31 Me OMe H  C-CON(Me) CH2(COOMe)2 
 15f  0.239 0.156 1.17 0.306  
33 Me OMe H  C-CON(Me) CH2COOH 
 38 >20 0.266 0.112 0.185 0.21 -6.23 
(11//3) 
34 Me OMe H  C-CONH (CH2)2COOH 
 92 13 0.404 >1 1.42 1.47  
35Z Me OMe H  C-Br H 100a 2.5 0.0368 0.442 0.309 0.346  
36Z Me OMe H  C-Br Br 100a 1.1 0.165 0.194 0.695 0.191 -10.07 
(2//47) 
37/38 Me OMe H  N H 93 2.2 0.032 0.034 0.031 0.032 -9.40 
(1//100) 
37/38 - OMe H  NMe H 49 ≈20 0.03 0.22 0.028 0.029 -9.13 
(1//96) 
a Percentage tubulin polymerization inhibitory (TPI) activity at the indicated concentration. b Tubulin 
polymerization inhibitory (TPI) IC50. c Values are derived from concentration-response curves using the 
XTT assay as described in the Experimental Section. Data are shown as the mean values of three 
experiments performed in triplicate. d AutoDock Binding Energies in kcal/mol for the best pose of the 
cluster with number representing the indicated number of poses out of a total of 100. e At 5µM. f At 
10µM. 
 
For all the pairs differing only in the disposition of the methoxy groups of ring A (e.g., compare the 
matched couples 15/16Z, 17/18, 19/20, 21/22, 23/24 and 25/26), the compounds with a 2,3,4-
trimethoxyphenyl (like that of colchicine) were less potent than those with a 3,4,5-trimethoxyphenyl 
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ring (like those of podophyllotoxin and combretastatin A4), similar to what has been reported 
previously.22 Comparison of 13 and 14 with 15 and 17 respectively, shows that a methyl is slightly 
preferred over an ethyl on the indole nitrogen.  
Substitutions at the indole 3 position (e.g. 17, 19, 21, 23 and 25) result in an overall potency increase 
with respect to the unsubstituted 15 for the 3,4,5-trimethoxyphenyl substituted compounds whereas an 
opposite trend is seen for compounds with a 2,3,4-trimethoxyphenyl (e.g., compare 18, 20, 22, 24 and 
26 with 16Z). This different behavior probably arises from steric hindrance, as larger groups result in 
more reduced potencies, in agreement with previous results on the isocombretastatins where indole 
substitution causes a reduction in potency.13 We have previously shown that substituents protruding out 
of the plane of ring B in isocombretastatins result in less potent compounds.23  
 
The optimal substitutions at the indole 3 position are the hydroxyiminomethyl (21) and the cyano (23) 
groups, which are nanomolar or subnanomolar in the four cell lines assayed. The formyl substituent (17) 
provides also high potency against HeLa and HL60, but there is a significant potency drop down to the 
micromolar range for A549 and HT-29. For the second potency level (two digit nanomolar), carboxy 
(25), methoxycarbonyl (27) and hydroxymethyl (19) indoles and the N-methylbenzimidazoles (37, 38) 
show similar potencies in the four cell lines. Larger substitutions at the three position (29, 34) result in a 
significant potency reduction, although most of them are still in the submicromolar range.  
 
The effect of the compounds on in vitro bovine brain tubulin assembly was studied at concentrations 
between 5 and 20 μM (Table 2). For those compounds inhibiting tubulin polymerization more than 50% 
at 20 μM we determined the IC50 values of tubulin polymerization inhibition (TPI). These values 
allowed us to compare the potencies of different compounds and to analyze the relationship between 
structure and TPI. Most of the compounds showed potent TPI inhibitory activity with values below 20 
µM, many better than combretastatin A4 (IC50 = 3 µM). As seen for the cytotoxicity assays, the 3,4,5-
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trimethoxyphenyl and 3 substituted N-methylindole combination was optimal, with several compounds 
(e.g. 17, 21, 23 and 27) showing submicromolar values. The compounds with a 2,3,4-trimethoxyphenyl 
ring showed reduced potencies, typically a ten - fold reduction as for example from 19 to 20. 
Substitution of the indole N-methyl by an N-ethyl modestly reduces the TPI potency. The TPI results 
show that aldehyde (17), hydroxyiminomethyl (21), nitrile (23), and methoxycarbonyl (27) substituents 
at the 3-position of the indole are optimal for tubulin inhibition. These groups share a sp2 carbonyl or 
equivalent conjugated with the indole ring and both hydrogen-bond donors and acceptors are allowed. 
Comparison of the TPI and cytotoxicity IC50 values shows that there is a good overall agreement 
between the TPI and the cytotoxic potencies against HeLa and HL60 cells, while the effects against A-
549 and HT-29 show in some cases significant deviations. These results suggest either a difference in 
the target (different tubulin isotype expression) or the involvement of an additional effect (drug efflux, 
drug metabolism, or other) to account for the observed potency reduction in these cell lines. 
 
Figure 2. Effects of compounds 17, 21 and 23 on the microtubule network of Hela cells. Cells were 
incubated in the absence (Control) or in the presence of 10 or 100 nM of compounds 17, 21 and 23 for 
15 h and then fixed and processed to analyze microtubules (red fluorescence) and nuclei (blue 
fluorescence) as described in the Experimental Section. Bar: 25 µm. The photomicrographs shown are 




The three compounds that showed a lower IC50, namely 17, 21 and 23, led to a drastic and severe 
disruption of the microtubule network of HeLa cells at nanomolar concentrations (Figure 2), further 
confirming that the observed effects were due to interaction with tubulin. Dose-response and time-
course analyses of the most active compounds synthesized in this work (16E, 17, 21, 23, 25, 27, 30) 
showed a major cell cycle arrest at G2/M phase (Figure 3), followed by the induction of apoptotic cell 
death, as assessed by an increase in the percentage of cells at the sub-G0/G1 region, representing cells 
undergoing chromosomal DNA degradation (Supplementary Table S1).  
 
Figure 3. Effect of different compounds on the distinct cell cycle phases in HeLa cells. Compounds 
16E, 17, 21, 23, 25, 27 and 30 were incubated for 15 h and then their DNA content was analyzed by 
flow cytometry as described in the Experimental Section. The different cell cycle phases were 
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quantified and represented in pie charts to easily visualize the changes in G2/M arrest. Untreated control 






Compound 23 was the most active one in arresting most of the cells (74.2%) at the G2/M phase at only 
1 nM concentration and after 15 h incubation, followed by compound 21 (79.9%) and 17 (59.3%), 
which required 10 nM concentration (Supplementary Table S1, and Figure 3).  
 
Figure 4. Time-course of the effects of compounds 21 and 23 on cell cycle in HeLa cells. Cells were 
incubated with 1 or 10 nM of 21 and 23 for the indicated times, and their DNA content was analyzed by 
fluorescence flow cytometry. The positions of the G0/G1 and G2/M peaks are indicated by arrows, and 
the proportion of cells in each phase of the cell cycle was quantified by flow cytometry. The cell 
population in the sub-G0/G1 region represents cells with hypodiploidal DNA, an indicator of apoptosis, 
and the percentages of cells at this region are indicated in each histogram. Untreated control cells were 





Figure 4 shows a time-course of the effects of the most active analogs 23 (active at 1 nM) and 21 (active 
at 10 nM) on the cell cycle profile of HeLa cells. G2/M cell cycle arrest was evident even at only 9 h 
treatment, and the onset of apoptosis took place after 24 h incubation, and the cell death response was 
almost complete after 72 h treatment (Figure 4). Taken together, these data indicate that the actions of 
23 and 21 on microtubules lead to a total disruption of microtubules that triggers a potent apoptotic 
response, rendering a complete cell demise in the drug-treated population. Caspase-3 activation was 
observed following treatment of HeLa cells with 23, as assessed by the processing of procaspase-3 into 
the p17/p19 active form, and the cleavage of the typical caspase-3 substrate PARP into the 89-kDa 
cleaved form (Supplementary Figure S1). Interestingly, the combined incubation of 21 or 23 and 10 µM 
verapamil, a concentration that had been previously reported not to decrease cell viability,24, 25 highly 
potentiated the cytotoxic activity of both 21 and 23 to IC50 of 10-10 M in A549 cells (Figure 5). 
Furthermore, the compound 17 became very active against A549 cells (IC50 = 5.98 x 10-8 M) when 
combined with 10 µM verapamil. These data suggest that the P-glycoprotein and calcium antagonist 
verapamil highly potentiate the cytotoxicity rendered by these newly synthetized combretastatin A-4 
derivatives.  
 
Figure 5. Effect of verapamil on the sensitivities of A549 cancer cells to 21 and 23. Cells were co-
incubated with verapamil and different concentrations of 21 and 23. The dose–response curves were 
drawn using the GraphPad Prism 5 software. Results are mean values ± S.D. of a representative 




The different effect of the 3-substituents on the indole ring of isomeric combretastatins and 
isocombretastatins on their potency could be explained by their topological differences. Therefore, the 
preferred conformations of the compounds were calculated, DFT-optimized and those conformations 
better superimposing onto the X-ray crystal structure of combretastatin A-4 when in complex with 
tubulin (pdb ID 1LYJ)26 were selected as the putative conformations binding to the colchicine site of 
tubulin. Figure XRAY shows the superimposition of the unsubstituted (a, 15) and 3-cyano indole 
combretastatins (b, 23 with a 3,4,5-trimethoxyphenyl ring and c, 23 with a 2,3,4-trimethoxyphenyl ring) 
and isocombretastatins (d and e) onto combretastatin A4 (carbon atoms colored in cyan). All of them 
place the phenyl rings close to those of combretastatin A4 to comply with the essential role assigned by 
pharmacophoric models for ligands of the colchicine site to their spatial arrangement. The single atom 
sp2 hybridized connection between the phenyl rings of isocombretastatins results in a wider opening 
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angle between the ring centroids and the bridge than in a stilbene (Fig d and e). When in complex with 
tubulin this disposition of the rings either projects the 3 substituents at positions further away probably 
colliding with the site walls or forces the displacement of the trimethoxyphenyl ring in the opposite 
direction towards the site walls thus resulting in the observed potency reduction. Similarly, a 2,3,4-
trimethoxyphenyl ring is more sterically demanding (Fig c) in the plane of the B – ring and trying to 
accommodate it in the colchicine site pushes the indole ring in the opposite sense. Substituents at the 
indole 3-position further worsen the steric problem and explains the potency decrease proportional to 
substituent size.  
 
Figure 6. Best superpositions of the X-ray structure of combretastatin A4 (in cyan) in the complex 
with tubulin and the conformations of representative compounds showing the effects of the structural 
modifications and the corresponding docking results (the protein is shown in grey): a) with 15; b) with 
23; c) with 24; d) with the 11,diarylethene isomer (isocombretastatin) of 15 and e) with the 
11,diarylethene isomer (isocombretastatin) of 24 and f) a combination of b,c and e. 
a)  b)  
c)  d)   
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e)  f)  
 
Docking experiments using AutoDock 4.2 on the X-ray structure of tubulin in complex with 
combretastatin A4 (pdb ID: 5LYJ) yielded results in excellent agreement with the experimental TPI and 
cytotoxicity results (Table 2) and with the results of the conformational study. When other X-ray 
structures of tubulin (15 different structures obtained from X-ray crystal structures of tubulin in complex 
with less structurally related ligands of the colchicine site or structures derived from molecular 
dynamics simulations, as previously described13) yielded worse results. The docking binding energy 
differences between compounds with a 3,4,5-trimethoxyphenyl (15, 17, 19, 21, 23, and 25) and their 
matched pairs with a 2,3,4-trimethoxyphenyl ring (16, 18, 20, 22, 24, and 26, respectively) is ca 0.6 
kcal/mol, in good agreement with the differences observed for TPI IC50 values. Also, for the former 
group the lowest energy clusters correspond to the same ring dispositions as seen for combretastatin A4, 
whereas for the second group the clusters with this ring disposition are usually second or worse by 
energy, being usually surpassed by dispositions with the two phenyl rings switched. For the most potent 
analogues (15, 17, 19, 21, 23, 25 and 27) the rank order of binding energies (21, 23, 19, 17, 27, 15, 25, 
19, CA-4) roughly matches the TPI values (23, 21, 17, 27, 19, 25, 15, CA-4), in spite of the fact that the 
energy differences between them are probably too small to be safely trusted. For the extended amides 




The replacement of the B ring of combretastatin A4 by 3 substituted indoles results in highly potent 
tubulin inhibition and cytotoxicity against several human cancer cell lines. This effect of the indole 3 
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substituents is highly context dependent, as it has been shown to be detrimental in the isomeric 
isocombretastatins or in compounds with a 2,3,4-trimethoxyphenyl ring. The optimal substituents are 
the cyano and hydroximinomethyl groups, whose compounds display high potency in all the studied cell 
lines, whereas compounds with other substituents show different potencies in different cell lines. Co-
treatment with verapamil restores high potency in these later compounds, thus suggesting a resistance 
based on MDR efflux proteins. The lower effect observed of the co-treatment for the former compounds 
suggest a lower sensitivity to MDR efflux. The more potent compounds displayed low nanomolar 
cytotoxicity against several human cancer cell lines due to tubulin inhibition, complete G2/M cell cycle 
arrest after 15 h followed by a high apoptosis-like cell response after 48-72 h mediated by caspase-3 
activation. Molecular modeling studies support binding at the colchicine site and provide an explanation 
for the aforementioned SAR. These compounds are highly potent against cell lines intrinsically resistant 




1-Methyl-1H-indole-5-carbaldehyde (1) and 1-Ethyl-1H-indole-5-carbaldehyde (1) 
1.04 g (26 mmol) of NaOH and 20 mg of n-Bu4N+HSO4- were added to a stirred solution of 1H-indole-
5-carbaldehyde (2.0 g, 13,8 mmol) in 40 mL of dry CH2Cl2. After 1 hour at atmosphere temperature 3 
mL (40.2 mmol) of methyl iodide or ethyl bromide were added and the reaction was heated at 50ºC. 
After 3 days the reaction mixture was concentrated, re-dissolved in CH2Cl2, washed with brine, dried 
over anhydrous  Na2SO4, filtered and concentrated in vacuum to obtain 1,10 g (61%) of 1 and 1.48 g 
(62.0%) of 2.  
1-Ethyl-1H-indole-5-carbaldehyde (1): M.p.: 64-66 ºC (CH2Cl2/Hex). IR (KBr): 1703, 1605, 1307, 
769 cm-1. 1H NMR (200 MHz, CDCl3): δ 1.49 (3H, t, J = 7.2), 4.22 (2H, m), 6.66 (1H, d, J = 3.3); 7.22 
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(1H, d, J = 3.3), 7.42 (1H, d, J = 8.4), 7.78 (1H, dd, J = 8.4 and 1.4), 8.15 (1H, d, J = 1.4), 10.0 (1H, s). 
13C NMR (50 MHz, CDCl3): δ 15.4 (CH3), 41.2 (CH2), 103.4 (CH), 109.9 (CH), 121.6(CH), 126.5 (CH), 
128.4 (C), 128.5 (CH), 129.3 (C), 139.0 (C), 192.5 (CH). 
1-Methyl-1H-indole-5-carbaldehyde (2): M.p.: 85-86ºC (Ether). 1H NMR (200 MHz, 
CDCl3): δ 3.76 (3H, s), 3.76 (3H, s) 6.55 (1H, d, J = 3.3), 7.10 (1H, d J = 3.3), 7.41(1H, d, J = 8.8), 7.80 
(1H, dd, J= 8.8 and 1.9), 8.05 (1H, d, J = 1.9), 9.92 (1H, s). 13C NMR (50 MHz, CDCl3): δ  32.6 (CH3), 
103.1 (CH), 109.8 (CH),121.4 (CH), 126.1 (CH), 128.2(C), 129.1 (C), 130.9 (CH), 139.8 (C), 192.3 
(CH). 
 
1-Ethyl-1H-indole-3,5-dicarbaldehyde (3): IR (film): 1687, 1662, 1191 cm-1. 1H NMR (200 MHz, 
CDCl3): δ 1.54 (3H, t, J = 7.2), 4.25 (2H, c, J = 7.2),7.44 (1H, d, J = 8.6), 7.84 (1H, s), 7.85 (1H, dd, J 
= 8.6 and 1.6), 8.73 (1H, d, J = 1.6), 9.99 (1H, s), 10.04 (1H, s). 13C NMR (50 MHz, CDCl3): δ 15.0 
(CH3), 42.1 (CH2), 110.8 (CH), 118.8 (C), 123.4 (CH),125.0 (C), 126.8 (CH), 131.7 (C), 139.7 (CH), 
140.1 (C), 184.5 (CH), 192.1 (CH). 
 
3-Bromo-1-methyl-1H-indole-5-carbaldehyde (4) and 2,3-Bibromo-1-methyl-1H-indole-5-
carbaldehyde (5) 
To a solution of 1-methyl-1H-indole-5-carbaldehyde (2.0 g, 12.58 mmol) in 4 mL of chloroform, 2.9 g 
(16.35 mmol) of N-bromosuccinimide were slowly added. After 24 h stirring at 0 ºC, the reaction 
mixture was evaporated to obtain 5.38 g of crude. After column chromatography on silica gel 
(Hex/EtOAc 7/3) 611mg (1.93mmol, 15.34%) of compound 5 and 540 mg (2.27 mmol, 18.04%) of 
compound 4 were obtained. 
3-Bromo-1-methyl-1H-indole-5-carbaldehyde (4): IR 1H NMR (200 MHz, CDCl3): δ  3.84 (3H, s), 
7.26 (1H, s), 7.40 (1H, d, J = 8.8), 7.84 (1H, dd, J = 8.8 and 1.9), 8.09 (1H, d, J = 1.9), 10.07 (1H, s). 
13C NMR (50 MHz, CDCl3): δ 33.3 (CH3), 91.7 (C), 110.2 (CH), 122.4 (CH), 124.9 (CH), 127.3 (C), 
129.5 (CH), 129.8 (C), 139.4 (C), 192.0 (CHO). 
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2,3-Dibromo-1-methyl-1H-indole-5-carbaldehyde (5): IR 1H NMR (200 MHz, CDCl3): δ  3.84 (3H, 
s), 7,40 (1H, d, J = 8.4), 7,85 (1H, dd, J = 1,0 and 7.4), 8.05 (1H, d, J = 0.8), 10.06 (1H, s). 13C NMR 
(50 MHz, CDCl3): δ 32.7 (CH3), 94.9 (C), 100.2 (C), 110.3 (CH), 117.0 (C), 118.4 (C), 122.8 (CH), 
126.9 (CH), 130.3 (C), 191.8 (CHO). 
Preparation of compounds 7-10 
To a suspension of 2,0 g (12.3 mmol) of 1H-benzo[d]imidazole-5-carboxylic acid in 50 mL of dry THF, 
in inert atmosphere was added 983 mg (24,7 mmol) of LiAlH4 and stirred 48 h at 65ºC. The reaction 
mixture was poured into EtOAc/ EtOH and was filtered, by evaporation to dryness 1,4 g (75%) of 
compound 7 was obtained. 
4.94 g (56.7 mmol) of MnO2 were added to a solution of 1.40 g (9.46 mmol) of 7 in 50 mL of MeOH. 
After 48 h at rt, the mixture was filtered over sílica and by evaporation 1.24 g (90%) of compound 8 was 
isolated. 
To a solution of 1.24 g (8.49 mmol) of 8 in 50 mL of CH2Cl2:H2O (3:2) was added 700 mg (17.5 mmol) 
of NaOH and and 40 mg of n-Bu4N+HSO4. After 1 h stirring 1.33 mL (21.2 mmol) of MeI were added. 
After 24 h After 3 days the reaction mixture was concentrated, re-dissolved in CH2Cl2. After 
chromatography on silica gel (CH2Cl2/EtOAc 85/15), 600 mg (44%) of a mixture 9 and 10 were 
obtained  
1H-benzo[d]imidazol-5-yl)methanol (7): 1H NMR (200 MHz, CDCl3): δ 4.60 (2H, s), 7.08 (1H, dd; J 
= 8.4 and 1.6); 7,45 (1H, d, J = 8.4), 7.49 (1H, bs), 7.94 (1H, s). 13C NMR (50 MHz, CDCl3): δ 65.9, 
(CH2), 115.2 (CH), 116.3 (CH), 121.3 (CH), 136.1 (C), 140.6 (C), 141.0 (C), 146.0 (CH). 
 
1H-Benzo[d]imidazole-5-carbaldehyde (8): 1H NMR (200 MHz, CDCl3): δ 7.55 (1H, d, J = 8.4), 7.65 
(1H, dd, J = 8,4 and 1.4), 8.01 (1H, bs), 8.24 (1H, s), 9.85 (1H, s). 13C NMR (50 MHz, CDCl3): δ 116.3 





carbaldehyde (10): 1H NMR (200 MHz, CDCl3): δ 3.60 (3H, s); 3.63 (3H, s), 7.17 (1H, d, J = 8.4), 
7,56 (1H, dd, J = 8.4 and 1.6),7.56 (1H, dd, J = 8.4 and 1.6), 7.59 (1H, d, J = 8.4), 7.61 (1H, s), 7.77 
(1H, s), 7.82 (1H, d, J = 1.6), 7.98 (1H, d, J = 1.6), 9.78 (1H, s), 9.79 (1H, s). 13C NMR (50 MHz, 
CDCl3): δ  31.2 (2) (CH3), 110.1 (CH), 111.8 (CH), 120.2 (CH), 123.2 (CH), 123.5 (CH), 123.8 (CH), 




To a suspension of triphenyl(3,4,5-trimethoxybenzyl)phosphonium bromide (1.67 g, 3.19 mmol) in dry 
THF (40 mL), at -40 ºC in argon atmosphere, nBuLi (1.6 M in hexane, 2.0 mL, 3.2 mmol) was added 
and stirred for 1 h. A solution of 1-ethyl-1H-indole-5-carbaldehyde (500 mg, 2.89 mmol) in dry THF 
(10 mL) was slowly added at -40 ºC and progressively warmed to room temperature. After 24 h, the 
reaction mixture was poured into ammonium chloride solution and extracted with CH2Cl2. The organic 
layers were washed to neutrality with brine, dried over anhydrous Na2SO4, filtered and evaporated to 
dryness. After chromatography on silica gel (Hex/AcOEt 85/15), 130 mg (0.40 mmol, 14%) of 13Z and 
161 mg (0.51 mmol, 18%) of a mixture 13Z/13E were obtained.  
(Z)-1-Ethyl-5-(3,4,5-trimethoxystyryl)-1H-indole (13): IR (film): 1685, 1579, 1127, 1007, 796, 722 
cm-1. 1H NMR (200 MHz, CDCl3): δ  1.51 (3H, t, J = 7.3), 3.62 (6H, s), 3.85 (3H, s), 4.18 (2H, c, J = 
7.3), 6.41 (1H, d, J = 3.1); 6.43 (1H, d, J = 12.3), 6.57 (2H, s), 6.72 (1H, d, J = 12.3), 7.08 (1H, d, J = 
3.1), 7.20 (1H, bs), 7.26 (1H, dd), 7.60 (1H, bs). 13C NMR (50 MHz, CDCl3): δ 15.5 (CH3), 41.1 (CH2), 
55.9 (2) (CH3), 60.9 (CH3), 103.3 (CH), 106.1 (CH), 108.9 (CH), 121.7 (CH), 122.8 (CH), 127.4 (CH), 
128.3 (C), 128.7 (C), 129.8 (CH), 131.4 (CH), 133.3 (C), 135.0 (C), 135.6 (C), 152.8 (2) (C). HRMS 




To a suspension of triphenyl(3,4,5-trimethoxybenzyl)phosphonium bromide (466 mg, 0.89 mmol) in dry 
THF (20 mL), at -40ºC in argon atmosphere, nBuLi (1.6 M in hexane, 0.56 mL, 0.89 mmol) was added 
and stirred for 1 h. The mixture was slowly added to a solution of 1-ethyl-1H-indole-3,5-dicarbaldehyde 
(189 mg, 0.89 mmol) in dry THF (10 mL) at -40 ºC and progressively warmed to room temperature. 
After 24 h, the reaction mixture was poured into ammonium chloride solution and extracted with 
CH2Cl2. The organic layers were washed to neutrality with saturated NaCl, dried over anhydrous 
Na2SO4, filetred and evaporated to dryness. By repeated chromatography with Hex/AcOEt 7/3 and 
CH2Cl2/AcOEt 96/4, aldehyde 14 (27 mg, 5.1%) was obtained. IR (film): 1655, 1459, 1397, 1124, 784 
cm-1. 1H NMR (400 MHz, CDCl3): δ 1.51 (3H, t, J = 7.2), 3.61 (6H, s), 3.82 (3H, s), 4.19 (2H, c, J = 
7.2), 6.51 (1H, d, J = 12.2), 6.50 (2H, s), 6.73 (1H, d, J = 12.2), 7.19 (1H, d, J = 8.8), 7.30 (1H, dd, J = 
8.8 and 2.0), 7.72 (1H, s), 8.26 (1H, bs), 9.96 (1H, s). 13C NMR (100 MHz, CDCl3): δ 15.1 (CH3), 42.0 
(CH2), 55.9 (2) (CH3), 61.0 (CH3), 106.2 (2) (CH), 109.4 (CH), 118.2 (C), 122.8 (CH), 125.2 (CH), 
125.6 (C), 129.4 (CH), 130.4 (CH), 132.3 (C), 132.9 (C), 136.0 (C), 137.2 (C), 137.6 (CH), 152.8 (2) 
(C), 184.4 (CH). MS: 365 (M+). HPLC: C18 tR: 19.9 min. 
 
(Z)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (15). Referencia 16c  
 
(Z)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole (16Z) 
To a stirred suspension of 2,3,4-Trimethoxybenzyltriphenylphosphonium bromide (1. 8 g, 3.46 mmol) 
in dry THF (10 mL), BuLi (1.6 M in hexane, 2.4 mL, 3.80 mmol) was added at -40 ºC under argon. 
After 1 h, 1-methyl-1H-indole-5-carbaldehyde (500 mg, 3.14 mmol) was added and the mixture was 
allowed to reach room temperature. After 12 h, the reaction mixture was poured onto ice with 
ammonium chloride and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 
and the solvent was evaporated in vacuo. The residue was purified by flash chromatography on silica 




(Z)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole (16Z): IR: 1596, 1493, 730 cm-1. 1H NMR (400 
MHz, CDCl3): δ 3.75 (3H, s), 3.83 (3H, s), 3.94 (6H, s), 6.41 (1H, bs), 6.45 (1H, d, J = 7.9), 6.58 (1H, d, 
J = 12.2), 6.78 (1H, d, J = 12.2), 6.98 (1H, d, J = 7.9), 7.02 (1H, bs), 7.16 (2H, m), 7.56 (1H, bs). 13C 
NMR (100 MHz, CDCl3): δ 32.8 (CH3), 56.0 (CH3), 61.1 (CH3), 61.2 (CH3), 101,3 (CH), 107.1 (CH), 
108.8 (CH), 121.5 (CH), 122.8 (CH), 123.0 (CH), 124.6 (CH), 124.9 (C), 128.4 (C), 128.7 (C), 129.1 
(CH), 131.1 (CH), 135.9 (C), 142.2 (C), 152.1 (C), 152.7 (C). HRMS (C20H21NO3 + Na): calcd 346.1413 
(M+ + Na), found 346.1401. HPLC: C18 tR: 22.4 min. 
 
(E)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole (16E): Mp 110-111ºC (Hexane). IR: 1492, 850 
cm-1. 1H NMR (400 MHz, CDCl3): δ 3.78 (3H, s), 3.90 (3H, s), 3.94 (3H, s), 3.95 (3H, s), 6.51 (1H, d, J 
= 3.4), 6.73 (1H, d, J = 8.6), 7.04 (1H, d, J = 3.4), 7.19 (1H, d, J = 16.5), 7.31 (1H, d, J = 8.6), 7.35 (1H, 
d, J = 8.6), 7.37 (1H, d, J = 16.5), 7.52 (1H, dd, J = 8.6 and J = 1.8), 7.76 (1H, d, J=1.8). 13C NMR (100 
MHz, CDCl3): δ 32.9 (CH3), 56.1 (CH3), 61.0 (CH3), 61.4 (CH3), 101.3 (CH), 107.9 (CH), 109.5 (CH), 
119.5 (CH), 120.0 (CH), 120.2 (CH), 120.3 (CH), 120.4 (CH), 125.3 (C), 128.8 (C), 129.4 (CH), 129.6 
(C), 136.5 (C), 142.2 (C), 151.5 (C), 152.8 (C). HRMS (C20H21NO3 + Na): calcd 346.1413 (M+ + Na), 
found 346.1401. HPLC: C18 tR: 23.1 min. 
(Z)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carbaldehyde (17) 
A solution of POCl3 (0.12 mL, 1.3 mmol) in DMF (1.0 mL) was stirred at 0 ºC for 1 h and then (Z)-5-
(3,4,5-trimethoxystyryl)-1-methyl-1H-indole (395 mg, 1.23 mmol) was added and heated at 60 ºC for 2 
h. After that, the reaction mixture was poured onto ice with sodium acetate, water (100 mL) was added 
and the mixture was keeped at 4 ºC. After 24 h the obtained precipitate was re-dissolved in CH2Cl2, 
dried over anhydrous Na2SO4, filtered, and concentrated in vacuum to obtain (Z)-N-methyl-5-[2-(3,4,5-
trimethoxyphenyl)vinyl]indole-3-carbaldehyde (17) (400 mg, 93%). M.p.: 144-146ºC. (CH2Cl2/Hex). IR 
(KBr): 1650, 1456, 1128 cm-1.  1H NMR (400 MHz, CDCl3): δ 3.62 (6H, s), 3.84 (3H, s), 3.86 (3H, s), 
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6.52 (2H, s), 6.52 (1H, d, J = 12.4), 6.73 (1H, d, J = 12.4), 7.18 (1H, d, J=9.2), 7.32 (1H, dd, J = 9.2 and 
2.2), 7.66 (1H, bs), 8.27 (1H, s), 9.98 (1H, s). 13C NMR (100 MHz, CDCl3): δ 33.5 (CH3), 55.8 (2) 
(CH3), 60.8 (CH3), 106.2 (2) (CH), 109.6 (CH), 117.9 (C), 122.4 (CH), 125.1 (CH), 125.2 (C), 129.2 
(CH), 130.3 (CH), 132.1 (C), 132.8 (C), 137.0 (C), 137.2 (C), 140.1 (CH), 152.8 (2) (C), 184.3 (CH). 
HRMS (C21H21NO4 + Na): calcd 374.1368 (M+ + Na), found 374.1343 HPLC: C18 tR: 14.66 min. C8 tR: 
13.42 min. Phenylic tR: 14.24 min. 
(Z)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole-3-carbaldehyde (18) 
POCl3 (360 mg, 2.3 mmol) in dry DMF (1 mL) at 0ºC was stirred for 30 min, then compound 16Z (720 
mg, 2.2 mmol) was added and the reaction was heated at 60ºC for 2 h. The reaction mixture was poured 
onto ice with sodium acetate, after 24 h at 2ºC, the solid obtained was filtered, solved in CH2Cl2, dried 
over Na2SO4 and the solvent evaporated in vacuo. The residue was purified by flash chromatography on 
silica gel with hexane/EtOAc (8:2) aldehyde 18 (661 mg, 85%). 1H NMR (400 MHz, CDCl3): δ 3.64 
(3H, s), 3.70 (3H, s), 3.90 (6H, s), 6.41 (1H, d, J = 8.6), 6.62 (1H, d, J = 12.1), 6.24 (1H, d, J = 12.1), 
6.84 (1H, d, J = 8.6), 7.11 (1H, d, J = 8.6), 7.20 (1H, d, J = 8.6), 7.51 (1H, s), 8.18 (1H, bs), 9.92 (1H, 
s). 13C NMR (100 MHz, CDCl3): δ 33.6 (CH3), 55.9 (CH3), 60.8 (CH3), 61.0 (CH3), 107.0 (CH), 109.3 
(CH), 118.1 (C), 122.5 (CH), 124.1 (CH), 124.3 (CH), 124.3 (C), 124.4 (CH), 124.7 (C), 130.1 (CH), 
132.5 (C), 136.8 (C), 139.2 (CH), 142.2 (C), 152.0 (C), 152.9 (C), 184.2 (CH). HRMS (C21H21NO4 + 
Na): calcd. 374.1368 (M+ + Na), found 374.1349. HPLC: C18 tR: 19.7 min. 
 
(Z)-(1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indol-3-yl)methanol (19) 
NaBH4 (20 mg, 0.07 mmol) was added to a stirred solution (Z)-N-methyl-5-[2-(3,4,5-
trimethoxyphenyl)vinyl]indole-3-carbaldehyde (24.6 mg, 0.07 mmol) in MeOH (10 mL). After half an 
hour, the methanol was evaporated and the residue was re-dissolved in CH2Cl2 and washed with brine. 
The organic layers were dried over anhydrous Na2SO4, filtered, and evaporated under vacuum to give 
(Z)-[N-methyl-5-[2-(3,4,5-trimethoxyphenyl)vinyl]indol-3-yl]methanol (19) (22 mg, 89%). IR (film): 
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3413, 1579, 1124 cm-1. 1H NMR (400 MHz, CDCl3): δ 3.64 (6H, s), 3.74 (3H, s), 3.84 (3H, s), 4.79 (2H, 
bs), 6.44 (1H, d, J = 12.2), 6.57 (2H, s), 6.71 (1H, d, J = 12.2), 7.02 (1H, s), 7.14 (1H, d, J = 8.6), 7.25 
(1H, dd, J = 8.6 and 1.8), 7.67 (1H, d, J = 1.8). 13C NMR (100 MHz, CDCl3): δ 32.8 (CH3), 56.0 (2) 
(CH3), 57.0 (CH2), 61.0 (CH3), 106.1 (2) (CH), 109.0 (CH), 115.0 (C), 120.0 (CH), 123.4 (CH), 127.0 
(C), 128.1 (2) (CH), 128.5 (C), 131.1 (CH), 133.3 (C), 136.6 (C), 137.0 (C), 152.9 (2) (C). HRMS. 
Calcd. for (C21H23NO4 + Na): calcd 376.1325 (M+ + Na), found 376.1525. HPLC: C18 tR: 14.82 min. C8  
tR: 13.50 min. Phenylic tR: 13.96 min. 
 
(Z)-(1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indol-3-yl)methanol (20) 
To a solution of aldehyde 18 (78 mg, 0.22 mmol) in MeOH (10 mL) at 0ºC and under argon, an excess 
of NaBH4 (62 mg) was added. After 15 min the MeOH was evaporated and the residue dissolved in 
CH2Cl2, the organic layer was washed with water, dried over Na2SO4 and the solvent evaporated in 
vacuo and by crystallization in MeOH, to produce alcohol 20 (40 mg, 50%) as a white solid. Mp: 135-
136ºC (CHCl3/ether). IR (KBr) 3424, 1600, 1490 cm-1. 1H NMR (400 MHz, CDCl3): δ 3.69 (3H, s), 3.81 
(3H, s), 3.93 (6H, s), 4.76 (2H, s), 6.42 (1H, d, J = 8.6), 6.56 (1H, d, J = 12.1), 6.72 (1H, d, J = 12.1), 
6.93 (1H, d, J = 8.6), 6.98 (1H, s), 7.10(1H, d, J = 8.5), 7.16 (1H, d, J = 8.5), 7.60 (1H, s), 7.82 (1H, bs). 
13C NMR (100 MHz, CDCl3): δ 32.6 (CH3), 55.9 (CH3), 56.8 (CH2), 60.9 (CH3), 61.0 (CH3), 107.0 
(CH), 108.9 (CH), 115.0 (C), 119.7 (CH), 123.0 (CH), 123.2 (CH), 124.4 (CH), 124.7 (C), 126.8 (C), 
127.9 (CH), 128.7 (C), 130.8 (CH), 136.3 (C), 142.2 (C), 152.0 (C), 152.7 (C). HRMS. Calcd. for 
(C21H23NO4 + Na): calcd 376.13519 (M+ + Na), found 376.1512. HPLC: C18 tR: 19.3 min. 
 
(Z+E)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carbaldehyde oxime (21Z+E) 
To a solution of aldehyde 17 (500 mg, 1.42 mmol) in MeOH (30 mL) hydroxylamine hydrochloride 
(987 mg, 14.2 mmol) and two drops of pyridine were added. After 24 at reflux, the solvent was 
evaporated, the obtained residue was solved in CH2Cl2 and extracted with H2O. The combined organic 
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layers were dried over Na2SO4 and evaporated to give a residue that was purified by silica gel flash 
chromatography using hexane/EtOAc (8:2) to yield the oximes 21 (280 mg, 73%) as a mixture (3:2) of 
Z and E isomers. 1H NMR (400 MHz, CDCl3): δ 3.62 (6H, s), 3.67 (6H, s), 3.75 (3H, s), 3.83 (3H, s), 
3.84 (3H, s), 3.86 (3H, s), 6.50 (1H, d, J = 12.6), 6.51 (1H, d, J = 12.6), 6.53 (2H, s), 6.58 (2H, s), 6.68 
(1H, d, J = 12.6), 6.73 (1H, d, J = 12.6), 7.13-7.40 (6H, m), 7.72 (1H, s), 7.73 (1H, s), 8.23 (1H, s), 8.24 
(1H, s). 13C NMR (100 MHz, CDCl3): δ 33.0 (CH3), 33.4 (CH3), 55.8 (2) (CH3), 55.9 (2) (CH3), 60.9 (2) 
(CH3), 106.0 (2) (CH),  106.1 (2) (CH), 108.8 (CH), 109.3 (CH), 109.1 (2) (C), 118.7 (CH), 122.7 (CH), 
124.2 (CH), 124.8 (CH), 128.3 (CH), 128.9 (CH), 129.8 (C), 130.3 (C), 130.5 (CH), 130.5 (C), 131.0 
(CH), 131.5 (CH), 132.9 (C), 133.5 (C), 135.2 (C), 135.9 (CH), 135.9 (C), 136.8 (C), 137.0 (C), 137.2 
(C), 145.3 (2) (CH), 152.8 (2) (C), 153.0 (2) (C). HPLC: C18 tR: 19.5 and 20.3 min. 
 
(Z+E)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole-3-carbaldehyde oxime (22Z+E): 1H NMR 
(400 MHz, CDCl3): δ 3.72 (3H,s), 3.77 (3H, s), 3.82 (6H, s), 3.92 (12H, s), 6.44 (1H, d, J = 8.8), 6.46 
(1H, d, J = 8.8), 6.60 (1H, d, J = 12.1), 6.62 (1H, d, J = 12.1), 6.75 (1H, d, J = 12.1).6.88 (1H, d, J = 
8.8), 6.91 (1H, d, J = 8.8), 7.15-7.35 (4H, m), 7.17 (1H, s), 7.26 (1H, s), 7.66 (1H,s), 7.68 (1H, s), 8.18 
(1H, s), 8.26 (1H, s). 13C NMR (100 MHz, CDCl3): δ 33.1 (CH3), 33.2 (CH3), 55.9 (CH3), 56.0 (CH3), 
60.9 (CH3), 61.0 (CH3), 105.5 (C), 107.1 (CH), 107.3 (CH), 109.0 (CH), 109.2 (C), 109.6 (CH), 118.6 
(CH), 120.5 (C), 121.4 (C), 122.7 (CH),  123.6 (CH), 123.7 (CH), 123.8 (CH), 124.2 (CH), 124.3 (C), 
124.4 (CH); 124.9 (CH), 125.2 (C), 125.5 (C), 127.2 (C), 130.2 (C), 130.3 (CH), 130.4 (CH), 130.9 
(CH), 134.9 (C), 135.3 (CH), 136.6 (C), 139.5 (CH), 142.2 (C), 145.5 (CH), 151.9 (C), 152.0 (C), 152.7 
(C), 152.8 (C). 
HPLC: C18 tR: 19.5 and 20.5 min. 
 




To a mixture of (Z+E) oximes 21 (80 mg, 0.21 mmol) or 22 (250 mg, 0.65 mmol) dissolved in pyridine 
(0.4 mL) or (1.25 mL) acetic anhydride (0.4 mL) or (1.25 mL) was added. After 9 h at room 
temperature, the reaction was treated with HCl 2N, extracted with CH2Cl2, washed with NaOH 2%, 
dried over anhydrous Na2SO4 and the solvent evaporated. The residue was purified by flash 
chromatography with hexane/EtOAc (1:1) yielding compound 23 (30 mg, 41%) or 24 (35 mg, 16%).  
 
(Z)-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carbonitrile (23): IR (film): 2217, 1579, 1504 
cm-1. 1H NMR (400 MHz, CDCl3): δ 3.63 (3H, s), 3.83 (3H, s), 3.85 (6H, s), 6.50 (2H, s), 6.53 (1H, d, J 
= 12.2), 6.68 (1H, d, J = 12.2), 7.21 (1H, d, J = 8.6), 7.30 (1H, d, J = 8.6), 7.52 (1H, s), 7.69 (1H, s). 13C 
NMR (100 MHz, CDCl3): δ 33.6 (CH3), 55.9 (2) (CH3), 60.9 (CH3), 85.6 (C), 106.1 (2) (CH), 109.8 
(CH), 115.6 (C), 120.3 (CH), 125.1 (CH), 127.8 (C), 129.7 (2) (CH), 131.5 (C), 132.6 (C), 135.0 (C), 
135.7 (CH), 137.3 (C), 152.9 (2) (C). HRMS (C21H20N2O3 + Na): calcd 371.1366 (M+ + Na), found 
371.1353. HPLC: C18 tR: 20.9 min. 
(Z)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole-3-carbonitrile (24): IR: 2216, 1596, 1490 cm-1. 
1H NMR (400 MHz, CDCl3): δ 3.73 (3H, s), 3.90 (9H, s), 6.43 (1H, d, J = 8.6), 6.65 (1H, d, J = 12.1), 
6.71 (1H, d, J= 12.1), 6.83 (1H, d, J = 8.6), 7.16 (1H, d, J = .8), 7.24 (1H, d, J = 8.6), 7.50 (1H, s), 7.63 
(1H, s). 13C NMR (100 MHz, CDCl3): δ 33.5 (CH3), 55.9 (CH3), 60.8 (CH3), 60.9 (CH3), 85.6 (C), 107.1 
(CH), 109.8 (CH), 115.6 (C), 120.1 (CH), 124.0 (C), 124.2 (CH), 124.8 (CH), 125.0 (CH), 127.8 (C), 
129.1 (CH). 131.8 (C), 135.0 (C), 135.7 (CH), 142.3 (C), 152.0 (C), 153.0 (C). HPLC: C18 tR: 20.5 min. 
(Z)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxylic acid (25) and (Z)-1-Methyl-5-
(2,3,4-trimethoxystyryl)-1H-indole-3-carboxylic acid (26) 
A solution of 80% NaClO2 (1.03 g, 11.4 mmol) and NaH2PO4·2H2O (1.02 g, 8.53 mmol) in water (15 
mL) was added at 0ºC to a suspension of aldehyde 17 (200 mg, 0.57 mmol) or 18 (200 mg, 0.57 mmol) 
in tert-butyl alcohol (15 mL) and 2-methylbut-2-ene (15 mL). THF (5 mL) was added to dissolve 
starting aldehyde 17 or 18 and the mixture was stirred at room temperature for 12 h. After dilution with 
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water (30 mL), the product was extracted with CH2Cl2, washed with brine, dried over anhydroud 
Na2SO4 and evaporated. By crystallization in MeOH (Z)-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-
indole-3-carboxylic acid (25) (150 mg, 72% ) or 26 (180 mg, 86%)  were obtained.  
(Z)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxylic acid (25): M.p.: 164-165ºC 
(MeOH). IR (KBr): 3450, 1620, 1502 cm-1. 1H NMR (400 MHz, CDCl3): δ 3.64 (6H, s), 3.82 (3H, s), 
6.50 (1H, d, J = 12.1), 6.51 (2H, s), 8.76 (1H, d, J = 12.1), 7.18 (1H, d, J = 8.5), 7.28 (1H, d, J = 8.5), 
7.83 (1H, s), 8.20 (1H, s). 13C NMR (100 MHz, CDCl3): δ 33.5 (CH3), 55.8 (2) (CH3), 60.8 (CH3), 106.1 
(2) (CH), 106.3 (C), 109.3 (CH), 122.4 (CH), 124.3 (CH), 126.8 (C), 128.9 (CH), 130.6 (CH), 131.4 
(C), 132.9 (C), 136.4 (C), 136.5 (CH), 137.1 (C), 152.8 (2) (C), 169.8 (C). HRMS (C21H21NO5 + Na): 
calcd. 390.1311 (M+ + Na), found 390.1318. HPLC: C18 tR: 23.2 min. 
 
(Z)-1-Methyl-5-(2,3,4-trimethoxystyryl)-1H-indole-3-carboxylic acid (26): M.p.: 189-190ºC 
(MeOH). IR (KBr): 1660, 1520 cm-1. 1H NMR (400 MHz, CDCl3): δ 3.92 (s, CH3), 3.93 (s, CH3), 3.94 
(s, CH3), 3.96 (s, CH3), 6.72 (1H, d, J = 8.7), 7.20 (1H, d, J = 12.4), 7.33 (1H, d, J = 12.4), 7.31 (1H, d, 
J = 8.7), 7.35(1H, d, J = 8.7), 7.37 (1H, s), 7.57 (1H, d, J = 8.7), 7.84 (1H, s), 8.29 (1H, bs). 13C NMR 
(100 MHz, CDCl3): δ 33.6 (CH3), 56.0 (CH3), 60.8 (CH3), 61.3 (CH3), 106.3 (C), 107.8 (CH), 110.0 
(CH), 120.4 (CH), 120.6 (CH), 121.1 (CH), 121.6 (CH), 124.9 (C), 127.1 (C), 128.9.1 (CH), 132.5 (C), 
136.6 (CH), 136.8 (C), 142.4 (C), 151.5 (C), 152.9 (C), 169.9 (C) . HPLC: C18 tR: 20.6 min. 
 
(Z)-Methyl 1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxylate (27) 
To a solution of the acid 25 (50 mg, 0.136 mmol) in MeOH (10 mL) (trimethylsilyl)diazomethane (2 
mL) was added. After 15 min at room temperature, the solvent was evaporated obtaining compound 27 
in quantitative yield. IR (film: 1699, 1570, 1503 cm-1. 1H NMR (400 MHz, CDCl3): δ 3.62 (6H, s), 3.78 
(3H, s), 3.84 (3H, s), 3.85 (3H, s), 6.49 (1H, d, J = 12.2), 6.54 (s, 2H), 6.65 (1H, d, J = 12.2), 7.20 (1H, 
d, J = 8.9), 7.25 (1H, d, J = 8.9), 7.73 (1H, s), 8.14 (1H, s). 13C NMR (100 MHz, CDCl3): δ 33.5 (CH3), 
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51.0 (CH3), 55.9 (2) (CH3), 60.9 (CH3), 106.1 (2) (CH), 107.1 (C), 109.3 (CH), 122.2 (CH), 124.4 (CH), 
126.4 (C), 128.8 (CH), 130.7 (CH), 131.0 (C), 133.1 (C), 135.6 (CH), 136.3 (C), 137.0 (C), 152.8 (2) 
(C), 165.4 (C). HRMS (C22H23NO5 + Na): calcd. 404.1468 (M+ + Na), found 404.1463. HPLC: C18 tR: 
21.6 min. 
Preparation of compounds 28-31 
A mixture of carboxilic acid (25) (1 mmol); 1 mmol of the corresponding aminoester: glycine ethyl ester 
hydrochloride, sarcosine methyl ester, β-alanine ethyl ester or  dimethylamino malonate hydrochloride; 
2 mmol of EDCI and 0.5 mmol of 4-DAMP were disolved in dry CH2Cl2 in inert atmosphere. After 72 h 
at room temperature, the reaction was treated with HCl 2N, extracted with CH2Cl2, washed with NaOH 
2%, dried over anhydrous Na2SO4 and the solvent evaporated. The residue was purified by flash 
chromatography with hexane/EtOAc or crystallization  yielding the compounds 28 (72%), 29 (55 %), 30 
(54%) and 31 (30%) + 25 (20%). 
(Z)-Ethyl 2-(1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)acetate (28): IR (film): 
3347, 1744, 1638, 1578 cm-1. 1H NMR (200 MHz, CDCl3): δ  1.22 (3H, t, J = 7.2), 3.52 (3H, s), 3.76 
(3H, s), 3.90 (2H, m ), 4.14 (2H, c, J = 7.2), 6.41 (1H, d, J = 12.2), 6.46 (2H, s), 6.62 (1H, d, J = 12.2), 
6.97 (1H, d, J = 8.6), 7.16 (1H, d, J = 8.6), 7.54 (1H, s), 8.01 (1H, s). 13C NMR (50 MHz, 
CDCl3): δ 14.2 (CH3), 33.2 (CH3), 41.3 (CH3), 55.8 (CH3), 60.9 (CH3), 61.4 (CH2), 106.0 (CH), 109.3 
(C), 109,8 (CH), 121.5 (CH), 123.7 (CH), 125.8 (C), 128.7 (CH), 130.5 (C), 130.8 (CH), 132.5 (CH), 
133.1 (C), 136.2 (C), 152.8 (C), 165.2 (C), 170.9 (C). HRMS (C25H28N2O6 + Na): calcd. 475.1839 (M+ + 
Na), found 475.1861. 
(Z)-Methyl 2-(N,1-dimethyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)acetate (29): IR 
(film): 3052, 2834, 1746, 1617, 1581 cm-1. 1H NMR (200 MHz, CDCl3): δ 3.09 (3H, s), 3.58 (6H, s), 
3.71 (3H, s), 3.78 (3H, s), 4.20 (2H, s), 6.44 (1H, d, J = 12.2), 6.47 (2H, s), 6.67 (1H, d, J = 12.2), 7.12 
(1H, d, J = 8.8), 7.20 (1H, d, J = 8.8), 7.34 (1H, s), 7.72 (1H, s). 13C NMR (50 MHz, CDCl3): δ 33.1 
(CH3), 50.0 (CH2), 52.0 (CH3), 58.8 (CH3), 60.7 (CH3), 106.0 (CH), 109.2 (CH), 109.5 (C), 121.7 (CH), 
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123.7 (CH), 126.6 (C), 128.5 (CH), 130.1 (C), 130.8 (CH), 131.7 (CH), 133.1 (C), 135.6 (C), 136.8 (C), 
157.7 (C), 167.5 (C), 170.0 (C). HRMS (C25H28N2O6 + Na): calcd. 475.1839 (M+ + Na), found 475.1846. 
(Z)-Ethyl 3-(1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)propanoate (30): M.p.: 
133-134ºC (MeOH). IR (KBr): 3359, 1727, 1611, 1579, 1512 cm-1. 1H NMR (200 MHz, 
CDCl3): δ 1.28 (3H, t, J = 7.2), 2.64 (2H, t, J = 6.1), 3.61 (6H, s), 3.73  (2H, t, J = 6.1), 3.76 (3H, s), 
3.82 (3H, s), 4.16 (2H, c, J = 7.2), 6.49 (1H, d, J = 12.2), 6.51 (2H, s), 6.73 (1H, d, J = 12.2), 7.15 (1H, 
d, J = 8.6), 1.25 (1H, d, J = 8.6), 7.59 (1H, s), 7.92 (1H, s). 13C NMR (50 MHz, CDCl3): δ 14.2 (CH3), 
33.2 (CH3), 34.3 (CH2), 34.8 (CH2), 55.8 (CH3), 60.6 (CH2), 60.8 (CH3), 106, 0 (CH), 109.4 (CH), 
121.4 (CH), 123.7 (CH), 125.7 (C), 128.7 (CH), 10.8 (CH), 132.2 (CH), 133.1 (C), 136.3 (C), 152.8 (C), 
164.9 (C), 172.7 (C). HRMS (C26H30N2O6 + Na): calcd. 489.1996 (M+ + Na), found 489.2021. 
 
 (Z)-Dimethyl 2-(1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)malonate (31). IR 
(KBr): 1742, 1629, 1576 cm-1. 1H NMR (200 MHz, CDCl3): δ 3.61 (6H, s), 3.76 (3H, s), 3.81 (3H, s), 
3.86 (6H, s), 6.42 (1H, d, J = 6.6), 6.48 (1H, d, J = 12.0), 6.50 (2H, s), 6.68  (1H, d, J = 12.0), 6.88 (1H, 
d, J = 6.6),  7.13 (1H, d, J = 8.6), 7.24  (1H, d, J = 8.6), 7.66 (1H, s), 8.19 (1H, s). 
 
Preparation of compounds 32-34 
The compounds 28-30 were saponificated by treatment with KOH/MeOH 10% during 30’ at rt. 
Yielding thecompounds 32 (77%), 33 (84%) and 34 ( 90%) were obtained. 
 (Z)-2-(1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)acetic acid (32): M.p.: 144-
145ºC (MeOH). IR (KBr): 3412, 1735, 1640, 1578 cm-1. 1H NMR (200 MHz, CD3OD): δ 3.45 (3H, s), 
3.62 (3H, s), 3.72 (3H, s), 3.97 (2H, s), 6.40 (1H, d, J = 12.2), 6.46 (2H, d), 7.09 (1H, d, J = 8.6), 
7.24 (1H, d, J = 8.6), 7.71 (1H, s), 7.99 (1H, s). 13C NMR (50 MHz, CD3OD): δ 33.4 (CH3), 41.7 (CH2), 
56.2 (CH3), 61.0 (CH3), 107.4 (CH), 110.6 (CH), 110.0 (C), 122.6 (CH), 124.9 (CH), 127.6 (C), 129.9 
(CH), 131.9 (CH), 133.8 (CH), 134.6 (C), 137.8 (C), 154.0 (C), 167.8 (C), 173.6 (C). HRMS 
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(C23H24N2O6 + Na): calcd. 447.1526 (M+ + Na), found 447.15.39. 
(Z)-2-(N,1-dimethyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)acetic acid (33): IR 
(KBr): 3399, 3431, 1584, 1500 cm-1. 1H NMR (200 MHz, CD3OD): δ 3.02 (3H, s), 3.40 (3H, s), 3.61 
(3H, s), 3.68 (3H, s), 3.95 (3H, s), 6.37 (1H, d, J = 12.2), 6.43 (2H, s), 6.60 (1H, d, J = 12.2), 7.08 (1H, 
d, J = 8.6), 7.20 (1H, d, J = 8.6), 7.40 (1H, bs), 7.70 (1H, s). 13C NMR (50 MHz, CD3OD): δ 33.2 (CH3), 
37.5 (CH3), 51.0 (CH2), 56.2 (CH3), 61.0 (CH3), 107.4 (CH), 110.3 (CH), 110.5 (C), 122.5 (CH), 124.8 
(CH), 128.2 (C), 129.8 (CH), 131.5 (C), 131.9 (CH), 134.7 (C), 137.1 (C), 138.0 (C), 154.0 (C), 169.8 
(C), 177.7 (C). HRMS (C24H26N2O6 + Na): calcd. 461.1683 (M+ + Na), found 461.1658. 
(Z)-3-(1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole-3-carboxamido)propanoic acid (34): M.p.: 
169-170ºC (CH2Cl2/MeOH). IR (KBr): 3378, 1726, 1606, 1577, 1506 cm-1. 1H NMR (200 MHz, 
CDCl3): δ 2.60 (2H, s), 3.60 (6H, s), 3.70 (2H, m), 3.74 (3H, s), 3.80 (3H, s), 6.48 (1H, d, J = 12.2), 
6.52 (2H, s), 6.70 (1H, d, J = 12.2), 7.16 (1H, d, J = 8.2), 7.24 (1H, d, J = 8.2), 7.65 (1H, s), 7.85 (1H, 
s). 13C NMR (50 MHz, CDCl3): δ 33.8 (CH3), 34.3 (CH2), 34.9 (CH2), 55.9 (CH3), 60.9 (CH3), 106.0 
(CH), 109.6 (CH), 110.2 (C), 120.2 (CH), 124.0 (CH), 125.1 (C), 128.9 (CH), 130.6 (CH), 130.7 (C), 
133.1 (CH), 133.3 (C), 136.4 (C), 152.9 (C), 165.4 (C), 176.0 (C). HRMS (C24H26N2O6 + Na): calcd. 
461.1683 (M+ + Na), found 461.1696. 
3-Bromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (35) 
To a suspension of triphenyl(3,4,5-trimethoxybenzyl)phosphonium bromide (3.02 g, 5.80 mmol) in dry 
THF (40 mL), at -40ºC in argon atmosphere, nBuLi (1.6 M in hexane, 3.4 mL, 5.5 mmol) was added 
and stirred for 1 h. A solution of compound 5 (1.06 g, 4.45 mmol) in dry THF (15 mL) was slowly 
added at -40 ºC and progressively warmed to room temperature. After 24 h, the reaction mixture was 
poured into ammonium chloride solution and extracted with CH2Cl2. The organic layers were washed to 
neutrality with brine, dried over anhydrous Na2SO4, filtered and evaporated to dryness. After 
chromatography on silica gel (Hex/AcOEt 7/3), 260 mg (0.65 mmol, 15%) of 35Z and 989 mg (2.46 
mmol, 55%) of 35E were obtained.  
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(Z)-3-Bromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (35Z): IR (film): 1H NMR (200 MHz, 
CDCl3): δ  3.65 (6H, s), 3.75 (3H, s), 3.84 (3H, s), 6.47 (1H, d, J = 12.2), 6.56 (2H, s), 6.70 (1H, d, J = 
12.2), 7.04 (1H, s), 7.14 (1H, d, J = 8.6), 7.23 (1H, dd, J = 8.6 and 1.2), 7.55 (1H, d, J = 1.2). 13C NMR 
(50 MHz, CDCl3): δ 33.3 (CH3), 56.1 (2) (CH3), 61.0 (CH3), 89.8 (C), 106.1 (2) (CH), 109.1 (CH), 
119.9 (CH), 124.2 (CH), 128.1 (CH), 128.6 (CH), 129.1 (C), 129.8 (2) (C), 130.6 (CH), 132.9 (C), 
135.4 (C), 137.3 (C), 153.5 (2) (C). HRMS HPLC: C18 tR: 26.3 min. 
(E)-3-Bromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (35E) 
IR (film): 1578, 1503, 1170 cm-1. 1H NMR (200 MHz, CDCl3): δ  3.70 (3H, s), 3.88 (3H, s), 3.93 (6H, 
s), 6.77 (2H, s), 7.04 (1H, d, J = 16.4), 7.14 (1H, s), 7.18 (1H, d, J = 16.4), 7.26 (1H, d, J = 8.8), 7.48 
(1H, dd, J = 8.8 and 1.6), 7.66 (1H, d, J = 1.6). 13C NMR (50 MHz, CDCl3): δ 33.2 (CH3), 56.2 (2) 
(CH3), 61.0 (CH3), 89.7 (C), 103.3 (2) (CH), 109.9 (CH), 117.7 (CH), 121.3 (CH), 126.7 (CH), 127.7 
(CH), 128.4 (CH), 129.1 (2) (C), 129.7 (C), 133.7 (C), 136.1 (C), 153.4 (2) (C). 
 
2,3-Dibromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (36) 
To a suspension of triphenyl(3,4,5-trimethoxybenzyl)phosphonium bromide (1.07 g, 2.05 mmol) in dry 
THF (40 mL), at -40ºC in argon atmosphere, nBuLi (1.6 M in hexane, 1.2 mL, 1.92 mmol) was added 
and stirred for 1 h. A solution of compound 5 (500 mg, 1.58 mmol) in dry THF (10 mL) was slowly 
added at -40 ºC and progressively warmed to room temperature. After 24 h, the reaction mixture was 
poured into ammonium chloride solution and extracted with CH2Cl2. The organic layers were washed to 
neutrality with brine, dried over anhydrous Na2SO4, filtered and evaporated to dryness. After 
chromatography on silica gel (Hex/AcOEt 8/2 and 6/4), 324 mg (0.67 mmol, 42.4%) of 36Z and 174 mg 
(0.36 mmol, 23%) of a mixture 36Z/36E were obtained.  
(Z)-2,3-Dibromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (36Z): IR (film): 1580, 1503, 1170 
cm-1. 1H NMR (200 MHz, CDCl3): δ 3.64 (6H, s), 3.77 (3H, s); 3.84 (3H, s), 6.44 (1H, d, J = 12.0), 6.52 
(2H, s), 6.68 (1H, d, J = 12.0), 7.16 (1H, d, J = 8,8); 7,21 (1H, dd, J = 8.8 and 1.4), 7.49 (1H, d, J = 1.4). 
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13C NMR (50 MHz, CDCl3): δ 32.3 (CH3), 55.9 (2) (CH3), 60.9 (CH3), 92.7 (C), 106.1 (2) (CH), 109.2 
(CH), 115.0 (C), 119.1 (CH), 124.4 (CH), 126.7 (CH), 128.9 (CH), 129.8 (C), 130.2 (C), 132.9 (C), 
135.4 (C), 137.3 (C), 152.9 (2) (C). HRMS HPLC: C18 tR: 25.4 min. 
(E)-2,3-Dibromo-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-indole (36E): 1H NMR (200 MHz, 
CDCl3): δ  3.68 (3H, s), 3.89 (3H, s), 3.91 (6H, s), 6.74 (2H, s), 7.00 (1H, d, J = 16.4), 7,10 (1H, d, J = 
16.4), 7.15 (1H, d, J = 8.8), 7.39 (1H, bs, J = 8.8), 7.56 (1H, bs). 13C NMR (50 MHz, CDCl3): δ 32.3 
(CH3), 56.1 (2) (CH3), 60.9 (CH3), 92.8 (C), 103.3 (2) (CH), 109.9 (CH), 115.2 (C), 116.9 (CH), 121.4 
(CH), 126.9 (CH), 127.1 (C), 128.5 (CH), 130.3 (C), 133.4 (C), 135.9 (C), 137.7 (C), 153.4 (2) (C) 
HRMS HPLC: C18 tR: 21.5 min. 
 
(Z and E)-1-Methyl-5-(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole (37Z and 37E) and (Z and 
E)-1-methyl-6-(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole (38Z and 38E). 
(3,4,5-trimethoxybenzyl)triphenylphosphonium bromide (1.38 g, 2.63 mmol) was suspended in THF 
(18 mL) and cooled to -40 ºC under Ar, then nBuLi (1.6 M in hexane, 1.8 mL, 2.88 mmol) was added 
dropwise and the resulting solution was stirred for 1 h. A solution of a 1:1 mixture of 1H-benzimidazol-
5-carbaldehyde and 1H-benzimidazol-6-carbaldehyde (383 mg, 2.39 mmol) in THF (15 mL) was added 
and warm to room temperature. Once completed, the reaction mixture was cooled to 0 ºC, quenched 
with some drops of water and extracted with dichloromethane. The organic layers were washed with 
brine, dried over anhydrous Na2SO4, and evaporated to give the crude of the reaction (1.48 g), which 
after chromatography on silica gel afforded one fraction of 1:1 mixture containing the Z-isomers of 1-
methyl-5-(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole and 1-methyl-6-(3,4,5-trimethoxystyryl)-1H-
benzo[d] imidazole (206 mg, 24%) and another 1:1 mixture containing the E-isomers of 1-methyl-5-
(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole and 1-methyl-6-(3,4,5-trimethoxystyryl)-1H-benzo[d] 




(Z)-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole (37Z) and (Z)-1-Methyl-6-(3,4,5-
trimethoxystyryl)-1H-benzo[d]imidazole (38Z). IR (film): cm-1. Major isomer: 1H NMR (400 MHz, 
CDCl3): δ 3.60 (6H, s), 3.74 (3H, s), 3.82 (3H, s), 6.49 (2H, s), 6.52 (1H, d, J = 12,1), 6.72 (1H, d, J = 
12,1), 7.22 (1H, d, J = 8,6), 7.29 (1H, s), 7.66 (1H, d, J = 8,6), 7.83 (1H, s). 13C NMR (100 MHz, 
CDCl3): δ 30.9 (CH3), 55.8 (2) (CH3), 60.9 (CH3), 106.0 (2) (CH), 109.6  (CH), 119.8  (CH) , 123.7  
(CH), 129.6  (CH), 130.2  (CH), 131.6 (C), 132.3 (C), 132.6 (C), 132.8 (C), 137.2 (C), 144.1 (CH), 
152.8 (2) (C). Minor isomer: 1H NMR (400 MHz, CDCl3): δ 3.61 (6H, s), 3.81 (3H, s), 3.83 (3H, s), 
6.50 (1H, d, J = 12.1), 6.50 (2H, s), 6.71 (1H, d, J = 12.1), 7.27 (1H, s), 7.29 (1H, d, J = 8.6), 7.65 (1H, 
m), 7.75 (1H, s). 13C NMR (100 MHz, CDCl3): δ 31.1 (CH3), 56.1 (2) (CH3), 60.9 (CH3), 106.0 (2) 
(CH), 108.8 (CH), 120.7 (CH), 124.4 (CH), 129.1 (CH), 130.3  (CH), 144.0 (CH), 153.4 (2) (C), five 
(C) were not observed. HRMS (C19H20N2O3+Na): calcd. 347.1366 (M++Na+), found 347.1365. HPLC: 
C18 tR: 13.83 and 13.93 min. (7:3). C8 tR: 13.08 and 13.14 min. (7:3).  Phenylic tR: 13.52 and 13.68 min. 
(7:3) 
 
(E)-1-methyl-5-(3,4,5-trimethoxystyryl)-1H-benzo[d]imidazole (37E) or (E)-1-methyl-6-(3,4,5-
trimethoxystyryl)-1H-benzo[d]imidazole (38E). IR (film): cm-1. 1H NMR (400 MHz, CDCl3): δ 3.84 
(3H, s), 3.87 (3H, s), 3.92 (6H, s), 6.76 (2H, s), 7.05 (1H, d, J = 16.4), 7.16 (1H, d, J = 16.4), 7.47 (1H, 
bs) , 7.49 (1H, dd, J = 8.4 and 1.8), 7.75 (1H, d, J = 8.4), 7.85 (1H, s). 13C NMR (100 MHz, CDCl3): δ 
31.2 (CH3), 56.2 (2) (CH3), 61.0 (CH3), 106.1 (2) (CH), 107.4 (CH), 120.2 (CH), 121.2 (CH), 128.0 
(CH), 128.6 (CH), 132.8 (C), 133.3 (C), 135.1 (C), 137.9 (C), 144.1 (CH), 143.4 (C), 153.5 (2) (C). 
HRMS (C19H20N2O3+Na): calcd. 347.1366 (M++Na+), found 347.1362. HPLC: C18 tR: 13.79 min. C8 tR: 
12.86 min. Phenylic tR: 13.42 min. 
 
Determination of Aqueous Solubility 
The aqueous solubility of the compounds was determined using an approach based on the saturation 
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shake-flask method. Approximately 2 mg of each compound was suspended in 0.3 mL pH 7.0 buffer in 
a glass vial and shaken 72 h at room temperature. The resulting mixture was filtrated over a 22 µm filter 
to discard the insoluble residues and the concentration in the supernatant was measured by UV 
absorbance in a Helios Alfa Spectrophotometer. Previously, for each compound the maximum 
wavelength of absorbance is determined and a calibration line is performed. 
 
Inhibition of tubulin polymerization 
Bovine brain tubulin was isolated as previously described.13 The assays were carried out at pH 6.7 
with 1.5 mg/mL protein and the measured ligand concentration in 0.1 M MES buffer, 1 mM EGTA, 1 
mM MgCl2, 1 mM β-ME, 1.5 mM GTP. The samples were incubated at 20 °C for 30 min and 
subsequently cooled on ice for 10 min. Tubulin polymerization was monitored by measuring the 
absorbance increase in the UV at 450 nm caused by a temperature shift from 4 ºC to 37 ºC. After 
reaching a stable plateau, temperature was switched back to 0 ºC and return to the initial absorption 
values was ascertained, in order to confirm the reversible nature of the monitored process. The 
difference in amplitude between the stable plateau and the initial baseline of the curves was taken as the 
degree of tubulin assembly for each experiment. Comparison with control curves with identical 
conditions but without ligands yielded tubulin polymerization inhibition as a percentage value. Initially, 
all compounds were assayed at a concentration of 5 µM in at least two independent measurements, and 
those displaying a TPI higher than 40% were selected for further studies. The tubulin polymerization 
inhibitory activity of the selected compounds was measured at different ligand concentrations and, as 
expected, the extent of inhibition by all compounds increased monotonically with the mole ratio of the 
total ligand to total tubulin in the solution. The obtained values were fitted to monoexponential curves 
and the IC50 values of tubulin polymerization inhibition were calculated from the best fitting curves.  
 
Cell culture. HL-60 (human acute myeloid leukemia) cell line was grown in RPMI-1640 culture 
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medium containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL 
penicillin, and 100 μg/mL streptomycin at 37 °C in humidified 95% air and 5% CO2. A549 (human 
non-small lung carcinoma), HeLa (human cervical carcinoma), and HT-29 (human colon carcinoma) 
cell lines were grown in DMEM culture medium containing 10% (v/v) heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in 
humidified 95% air and 5% CO2. Cells were periodically tested for Mycoplasma infection and found to 
be negative. 
 
Cell Growth Inhibition Assay. The effect of the different compounds on the proliferation of human 
tumor cell lines (cytostatic activity) was determined as previously described21 using the XTT (sodium 
3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)-benzenesulfonic acid hydrate) 
cell proliferation kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the 
manufacturer’s instructions. Cells (1.5 × 103 A549, HeLa, HT-29, and 3 × 103 HL-60 in 100 μL) were 
incubated in culture medium containing 10% heat-inactivated FBS in the absence and in the presence of 
the indicated compounds at different concentration ranges from 10−5 to 10−13 M, in 96-well flat-
bottomed microtiter plates, and following 72 h of incubation at 37 °C in a humidified atmosphere of 
air/CO2 (19/1), the XTT assay was performed. Measurements were performed in triplicate, and each 
experiment was repeated three times. The IC50 (50% inhibitory concentration) value, defined as the drug 
concentration required to cause 50% inhibition in cellular proliferation with respect to the untreated 
controls, was determined for each compound. Nonlinear curves fitting the experimental data were 
carried out for each compound. 
 
Cell Cycle Analysis. For cell cycle analyses, untreated and drug-treated HeLa cells ((2−4) × 105) were 
centrifuged and fixed overnight in 70% ethanol at 4 °C. Then cells were washed three times with PBS, 
incubated for 1 h with 1 mg/mL RNase A and 20 μg/mL propidium iodide at room temperature, and 
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analyzed with a Becton Dickinson fluorescence-activated cell sorter (FACSCalibur) flow cytometer 
(San Jose, CA) as described previously.27, 28 Quantification of apoptotic cells was calculated as the 
percentage of cells in the sub-G0/G1 peak in cell cycle analysis.27, 28  
 
Confocal Microscopy. HeLa cells were grown on 0.01% poly-L-lysine coated coverslips, and after 
drug treatment, the coverslips were washed three times with HPEM buffer (25 mM HEPES, 60 mM 
PIPES, 10 mM EGTA, 3 mM MgCl2, pH 6.6), fixed with 4% paraformaldehyde in HPEM buffer for 15 
min, and permeabilized with 0.5% Triton X-100 as previously described.14 Coverslips were incubated 
with a specific Ab-1 anti-α-tubulin mouse monoclonal antibody (diluted 1:150 in PBS) (Calbiochem, 
San Diego, CA) for 1 h, washed four times with PBS, and then incubated with CY3-conjugated sheep 
antimouse IgG (diluted 1:100 in PBS) (Jackson ImmunoResearch, West Grove, PA) for 1 h at 4 °C. 
After being washed four times with PBS, cell nuclei were stained with DAPI (Sigma, St. Louis, MO) for 
5−10 min and washed with PBS, and then the samples were analyzed by confocal microscopy using a 
ZeissLSM 310 laser scan confocal microscope. A drop of SlowFade light antifading reagent (Molecular 
Probes, Eugene, OR) was added to preserve fluorescence. Negative controls, lacking the primary 
antibody or using an irrelevant antibody, showed no staining. 
 
Western Blot. About 5 × 106 cells were pelleted by centrifugation, washed with PBS, lysed, and 
subjected to Western blot analysis as described previously.27 Proteins were separated through SDS 
polyacrylamide gels under reducing conditions, transferred to nitrocellulose filters, blocked with 5% 
defatted milk powder, and incubated overnight with anti-activated caspase-3 (1:1000 dilution) rabbit 
monoclonal antibody, which detects the full-length (35 kDa) and large fragment (17/19 kDa) of caspase-
3 (Cell Signaling Technology, Danvers, MA), or anti-poly(ADP-ribose) polymerase (PARP) (1:1000 
dilution) rabbit monoclonal antibody that detects the full-length PARP-1 and the large fragment (89 
kDa) produced by casopase cleavage (Cell Signaling Technology). Signals were developed using an 
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enhanced chemiluminescence detection kit (Amersham Biosciences, Aylesbury, UK). Immunoblotting 
with AC-15 anti-42 kDa β-actin (1:5000 dilution) mouse monoclonal antibody (Sigma) was used as an 
internal loading control, revealing equivalent amounts of protein in each lane of the gel. Prestained 
protein molecular mass standards (Bio-Rad) were run in parallel. 
 
Chemical Structure. Calculations were performed at the molecular mechanics level (MMFF94s), 
semiempirical level (AM1), and HF and B3LYP 6-31+G* DFT levels using the Spartan 08 and 
Gaussian G03 software packages. Conformational analyses with the MMFF94s forcefield were 
performed by systematically rotating in 18° steps the bonds between the bridges and the pending 
aromatic rings. The phenyl rings of the trimethoxybenzene rings obtained were superimposed over one 
another and over the trimethoxyphenyl ring of combretastatin A4 extracted from the X-ray crystal 
structure with tubulin (pdb: 5LYJ), and the conformations for which the phenyl ring of the indoles 
covered a region closer to the 3-hydroxy-4-methoxyphenyl ring of combretastatin A4 were subjected to 
further unrestrained energy minimization steps at the semiempirical (AM1), 6-31G** HF, and then 
B3LYP/6-31+G* DFT levels of theory. The conformations were then superimposed again onto 
combretastatin A4 by means of the Spartan 08 pharmacophore option, by selecting as pharmacophoric 
references the two aromatic rings of combretastatin A4 (hydrophobic), the two external oxygens of the 
trimethoxyphenyl moiety (hydrogen-bond acceptors), and the excluded volume, as calculated from the 
complex of combretastatin A4 with tubulin. 
 
Docking Experiments. The pdb structure data of the tubulin − combretastatin A4 complex 
(5LYJ.pdb)26 and 15 more complexes of colchicine site ligands with tubulin (1SA1.pdb, 3HKC,pdb, 
3HKD.pdb, 3HKE.pdb, 3N2G.pdb, 3N2K.pdb, 3UT5.pdb, 4O2A.pdb, 4O2B.pdb, 4YJ2.pdb, 4YJ3.pdb, 
5C8y.pdb, 5CA0.pdb, 5CA1.pdb, 5GON.pdb, 5CB4.pdb) were retrieved29 and chains C−E were 
removed. Five additional tubulin models were built from 1SA1.pdb after energy minimization and 
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molecular dynamics simulations at 300 K, initially with a restrained backbone and then with an 
unrestrained one using AMBER1430 and representative structures were selected as previously 
described.31 The ligands were built with Spartan 08, prepared with AutodockTools and docked with 
AutoDock 4.2,32, 33 by running the Lamarckian genetic algorithm (LGA) 100−300 times with a 
maximum of 2.5 × 106 energy evaluations, 150 individuals in the population, and a maximum of 27000 
generations, PLANTS34 and DOCK3.735. The results were analyzed with AutoDockTools,32, 33 with 
Marvin,36 OpenEye37 and with JADOPPT.38 Docking poses were selected if they were found by at least 




Figure 1. Representative combretastatin type ligands 
 
Figure 2. Effects of compounds 17, 21 and 23 on the microtubule network of Hela cells. Cells were 
incubated in the absence (Control) or in the presence of 10 or 100 nM of compounds 17, 21 and 23 for 
15 h and then fixed and processed to analyze microtubules (red fluorescence) and nuclei (blue 
fluorescence) as described in the Experimental Section. Bar: 25 µm. The photomicrographs shown are 
representative of at least three independent experiments performed. 
 
Figure 3. Effect of different compounds on the distinct cell cycle phases in HeLa cells. Compounds 
16E, 17, 21, 23, 25, 27 and 30 were incubated for 15 h and then their DNA content was analyzed by 
flow cytometry as described in the Experimental Section. The different cell cycle phases were 
quantified and represented in pie charts to easily visualize the changes in G2/M arrest. Untreated control 





Figure 4. Time-course of the effects of compounds 21 and 23 on cell cycle in HeLa cells. Cells were 
incubated with 1 or 10 nM of 21 and 23 for the indicated times, and their DNA content was analyzed by 
fluorescence flow cytometry. The positions of the G0/G1 and G2/M peaks are indicated by arrows, and 
the proportion of cells in each phase of the cell cycle was quantified by flow cytometry. The cell 
population in the sub-G0/G1 region represents cells with hypodiploidal DNA, an indicator of apoptosis, 
and the percentages of cells at this region are indicated in each histogram. Untreated control cells were 
run in parallel. The experiments shown were representative of three performed. 
 
Figure 5. Effect of verapamil on the sensitivities of A549 cancer cells to 21 and 23. Cells were co-
incubated with verapamil and different concentrations of 21 and 23. The dose–response curves were 
drawn using the GraphPad Prism 5 software. Results are mean values ± S.D. of a representative 
experiment carried out in triplicate, out of three performed. 
 
Figure 6 Best superpositions of the X-ray structure of combretastatin A4 (in cyan) in the complex with 
tubulin and the conformations of representative compounds showing the effects of the structural 
modifications and the corresponding docking results (the protein is shown in grey): a) with 15; b) with 
23; c) with 24; d) with the 11,diarylethene isomer (isocombretastatin) of 15 and e) with the 
11,diarylethene isomer (isocombretastatin) of 24 and f) a combination of b,c and e. 
 
Scheme 1: Synthesis of 3-indolecarbaldehyde combretastatin derivatives 13-16 and bromoderivatives 
35 and 36.a 
 (a) (i) (3,4,5-(MeO)3PhCH2)Ph3PBr (11), THF, BuLi (1.6M), THF, -40ºC, 1h; (ii) 1-ethyl-1H-indole-5-
carbaldehyde (1), 1-methyl-1H-indole-5-carbaldehyde (2), 1-ethyl-1H-indole-3,5-dicarbaldehyde (3), 1-
methyl-3-bromo-1H-indole-5-carbaldehyde (4) or 1-methyl-2,3-dibromo -1H-indole -5-carbaldehyde 
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(5), THF, -40 ºC to rt, 24 h. (b) (i) (2,3,4-(MeO)3PhCH2)Ph3PBr (12), THF, BuLi (1.6M), THF, -40ºC, 
1h; (ii) 1-methyl-1H-indole-5-carbaldehyde (2), THF, -40 ºC to rt, 24 h. 
 
Scheme 2: Preparation of benzimidazole combretastatin derivatives 37+38.a 
Reagents and conditions: (a) (i) Ph3P(3,4,5-MeO3PhCH2)I, THF, nBuLi (1.6M), THF, -40 ºC, 1h; (ii) 1-
methyl-1H-benzimidazole-5(6)-carbaldehydes, THF, -40 ºC to rt, 24 h. 
 
Scheme 3: Preparation of 3-substituted indole-combretastatin derivatives 17-34.a 
Reagents and conditions: (a) (i) POCl3, DMF, 0 ºC, 1 h; (ii) 15 or 16, 60 ºC, 2 h. (b) NaBH4, MeOH, rt, 
30 min. (c) NH2OH·HCl, MeOH, pyr (2 drops), rt, 24 h. (d) Ac2O, pyr, rt, 4 h. (e) 17 or 18 in tBuOH, 2-
methyl-2-butene, THF; add NaClO2, NaH2PO4, H2O, rt, 12 h. (f) TMSCHN2, MeOH, 15 min. (g) (i) 
NH2CH2COOEt·HCl; EDCI; 4-DMAP; rt, 48 h, inert atmosphere. (h) CH3NHCH2COOMe·HCl; EDCI; 
4-DMAP; rt, 48 h, inert atmosphere. (i) NH2CH2CH2COOEt; EDCI; 4-DMAP; rt, 48 h, inert 
atmosphere. (j) (COOMe)2CHNH2·HCl; EDCI; 4-DMAP; rt, 48 h, inert atmosphere. (k) KOH/MeOH, 
rt, 30 min. 
 
Table 1. Aqueous solubility of representative compounds in aqueous buffer pH 7.0 
Table 2. Tubulin Polymerization Inhibitory Activity, Cytotoxic Activity against Human Cancer Cell 
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